Product Name: Cot
Product Number: AB-NK042
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Osaka thyroid oncogene protein-serine kinase (Tpl2); Mitogen-activated protein kinase kinase kinase 8
Target Alias: FLJ10486; M3K8; MAP3K8; Tpl2; TPL2; TPL-2; tumour progression locus 2; Cot; ESTF; EST; Tpl-2; c-Cot; ENSG00000107968
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK042
Antibody Target Type: Pan-specific
Protein UniProt: P41279
Protein SigNET: P41279
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Cot (MAP3K8, TPL2) sequence peptide
Target Alias: FLJ10486; M3K8; MAP3K8; Tpl2; TPL2; TPL-2; tumour progression locus 2; Cot; ESTF; EST; Tpl-2; c-Cot; ENSG00000107968
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK042
Antibody Target Type: Pan-specific
Protein UniProt: P41279
Protein SigNET: P41279
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Cot (MAP3K8, TPL2) sequence peptide
Antibody Immunogen Sequence: MEYMSTGSDNKEEIDC
Antibody Immunogen Description: Corresponds to amino acid residues M1 to D15; N-terminus
Production Method: The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Immunogen Description: Corresponds to amino acid residues M1 to D15; N-terminus
Production Method: The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Storage Buffer: 100 mM Tris-glycine, pH 7.0
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months, but either 0.1% sodium azide or 0.05% Thimerasol should be added. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human Cot expressed in E. coli as a glutathione S transferase fusion protein.
Storage Buffer: 100 mM Tris-glycine, pH 7.0
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months, but either 0.1% sodium azide or 0.05% Thimerasol should be added. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human Cot expressed in E. coli as a glutathione S transferase fusion protein.
Antibody Species Reactivity: Human; Mouse; Rat
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Antibody Cross Reactivity: Cross-reacts with an unidentified 30 kDa protein in rat skeletal muscle.
Related Product 1: Cot-CT (Cot-2) pan-specific antibody (Cat. No.: AB-NK042-2)
Related Product 2: Cot-pS334 phosphosite-specific antibody (Cat. No.: AB-PK585)
Related Product 3: Cot (Cot-1) pan-specific antibody (Cat. No.: AB-NK042-1)
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Antibody Cross Reactivity: Cross-reacts with an unidentified 30 kDa protein in rat skeletal muscle.
Related Product 1: Cot-CT (Cot-2) pan-specific antibody (Cat. No.: AB-NK042-2)
Related Product 2: Cot-pS334 phosphosite-specific antibody (Cat. No.: AB-PK585)
Related Product 3: Cot (Cot-1) pan-specific antibody (Cat. No.: AB-NK042-1)
Scientific Background: Cot (TPL2, MAP3K8) is a protein-serine/threonine kinase of the STE group and STE-Unique family. It is essential in the TLR4 (recognizing LPS) MAPK/ERK-mediated response in the production of pro-inflammatory cytokines. Catalytic activity of Cot is lost with the K167R, or D270A mutations. IL-1 stimulated activity is decreased with S62A. This mutation will also inhibit IL-1 stimulated phosphorylation of T290 along with MEK phosphorylation when associated with A400. Full inhibition of IL-1 induced MEK phosphorylation and partial inhibition of autophosphorylation can occur with a T290A mutation. Partial inhibition of MEK phosphorylation and autophosphorylation has occurred with a T290A or T290E mutation. Partial impairment of MEK phosphorylation induced by IL-1 has been observed with a S400A mutation. When Cot is associated with A62, a complete loss of T290 and MEK phosphorylation occurs with a S400A mutation.
© Kinexus Bioinformatics Corporation 2017